103573-2 |
Cosmetic facility registration |
- |
^FDA package insert |
- |
Nar |
|
|
ACTIVE |
FDA package insert Cosmetic facility registration |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOCUMENT.REGULATORY |
|
103573-2 |
|
|
|
|
Both |
|
|
|
0 |
FDA insert Cosmetic facility reg |
|
|
|
N |
|
DOCUMENT.REGULATORY; FDA insert; Narrative; Report; SPL; Structured Product Labelling |
2.78 |
2.77 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: PROPERTY: Removed property not needed for FDA concepts; TIME_ASPCT: Removed time not needed for FDA concepts; |
0 |
103574-0 |
Dog dander Ab.IgE panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Dog dander IgE panel - Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.ALLERGY |
|
103574-0 |
|
|
|
|
Order |
|
|
|
0 |
Epid Allerg Dog IgE pl SerPl |
|
|
|
N |
|
Allergen; Allergens; ALLERGY TESTING; Canine; Dog hair; e005; e5; Epid Allerg Dog IgE pl; Immune globulin E; Immunoglobulin E; Pan; PANEL.ALLERGY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.77 |
2.77 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
103575-7 |
Cat epithelium Ab.IgE panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Cat epithelium IgE panel - Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.ALLERGY |
|
103575-7 |
|
|
|
|
Order |
|
|
|
0 |
Allergen Cat IgE pnl SerPl |
|
|
|
N |
|
Allergen; Allergen Cat IgE pnl; Allergens; ALLERGY TESTING; Epithelia; Feline; Felis domesticus; Immune globulin E; Immunoglobulin E; Pan; PANEL.ALLERGY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.77 |
2.77 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
103576-5 |
Horse dander Ab.IgE panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Horse dander IgE panel - Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.ALLERGY |
|
103576-5 |
|
|
|
|
Order |
|
|
|
0 |
Horse dander IgE pnl SerPl |
|
|
|
N |
|
Allergen; Allergens; ALLERGY TESTING; e003; e3; Equus spp; Horse dander IgE pnl; Immune globulin E; Immunoglobulin E; Pan; PANEL.ALLERGY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.77 |
2.77 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
103577-3 |
Albumin |
MCnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Albumin [Mass/volume] in Serum by Immunoassay |
|
ADD |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
103577-3 |
|
IA |
|
|
Both |
|
|
|
0 |
Albumin Ser IA-mCnc |
|
|
|
N |
|
Alb; Chemistry; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; Level; Mass concentration; MEIA; Point in time; Protein.albumin; QNT; Quan; Quant; Quantitative; Random; Serum; SR; SUDS |
2.77 |
2.77 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
10358-0 |
Teichoate Ab |
Titr |
Ser |
Pt |
SemiQn |
Immune diffusion |
|
ACTIVE |
Teichoate Ab [Titer] in Serum by Immune diffusion (ID) |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
10358-0 |
|
Immune diffusion |
|
|
Both |
|
|
|
0 |
Teichoate Ab Titr Ser ID |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Imm; Immunodiff; Immunodiffusion; Imun; Imune; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; Teichoic ac; Teichoic acid; Titer; Titered; Titre; Ttr |
2.75 |
1.0i |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
103588-0 |
Etizolam |
PrThr |
TissCo |
Pt |
Ord |
Confirm |
|
ACTIVE |
Etizolam [Presence] in Cord tissue by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/g |
|
|
|
|
|
|
DRUG/TOX |
|
103588-0 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Etizolam TissCo Ql Cfm |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Depas; DRUG/TOXICOLOGY; Drugs; etizolam; GCMS; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Y-7131 |
2.77 |
2.77 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
103589-8 |
Flualprazolam |
PrThr |
TissCo |
Pt |
Ord |
Confirm |
|
ACTIVE |
Flualprazolam [Presence] in Cord tissue by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/g |
|
|
|
|
|
|
DRUG/TOX |
|
103589-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Flualprazolam TissCo Ql Cfm |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; flualprazolam; FWF5L8D2BE; GCMS; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UNII-FWF5L8D2BE |
2.77 |
2.77 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
10359-8 |
Asialoganglioside GM1 Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Asialoganglioside GM1 IgM Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
10359-8 |
|
|
|
|
Observation |
|
|
|
0 |
GM1 Asialo IgM Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Asialo Gm1; AsialoGM1; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); Ganglioside asialo; GM1 Asialo; Immune globulin M; Immunoglobulin M; Monoasialoganglioside; Point in time; Random; Serology; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0i |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
103590-6 |
Bacterial vaginosis RNA |
PrThr |
Vagina |
Pt |
Ord |
Probe.amp |
|
ACTIVE |
Bacterial vaginosis RNA [Presence] in Vagina by Probe with amplification |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103590-6 |
|
Probe.amp |
|
|
Both |
|
|
|
0 |
B. vaginosis RNA Vagina Ql Probe amp |
|
|
|
N |
|
Amplif; Amplification; Amplified; Bac vag RNA; Bact; DNA NUCLEIC ACID PROBE; DNA probe; Microbiology; Ordinal; Point in time; PR; Probe amp; Probe with ampification; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103591-4 |
Comprehensive foot screening report |
Find |
^Patient |
Pt |
Doc |
|
|
ACTIVE |
Comprehensive foot screening report Document |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.MISC |
|
103591-4 |
|
|
|
|
Both |
|
|
|
0 |
Comp foot screen rpt Doc |
|
|
|
N |
|
Asympt; Asymptomatic; Comp foot screen rpt; DOC.MISC; Document; Finding; Findings; Lower extremity; MISC; Point in time; Random; Scn |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103592-2 |
Retinal eye screening report |
Find |
^Patient |
Pt |
Doc |
|
|
ACTIVE |
Retinal eye screening report Document |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.MISC |
|
103592-2 |
|
|
|
|
Both |
|
|
|
0 |
Retinal eye screen rpt Doc |
|
|
|
N |
|
Asympt; Asymptomatic; DOC.MISC; Document; Finding; Findings; MISC; Point in time; Random; Retinal eye screen rpt; Retinaldehyde; Retinene; Retinene 1; Scn; Vit A aldehyde; Vit A1 aldehyde; Vitamin A aldehyde; Vitamin A1 aldehyde |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103593-0 |
Cell growth |
PrThr |
Amniocytes |
Pt |
Ord |
Tissue culture |
|
ACTIVE |
Cell growth [Presence] of Amniocytes Qualitative by Tissue culture |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
103593-0 |
|
Tissue culture |
|
|
Both |
|
|
|
0 |
Cell growth Amniocytes Ql Tiss culture |
|
|
|
N |
|
C&S; Cult; Cultures; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SPEC; Tiss culture |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103594-8 |
Acetyl norfentanyl |
MCnc |
TissCo |
Pt |
Qn |
Confirm |
|
ACTIVE |
Acetyl norfentanyl [Mass/volume] in Cord tissue by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
pg/g |
|
|
|
|
|
|
DRUG/TOX |
|
103594-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Acetyl norfentanyl TissCo Cfm-mCnc |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Fentanyl metabolite; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Synthetic opioid |
2.77 |
2.77 |
|
|
|
|
|
|
|
pg/g |
|
|
|
0 |
103595-5 |
Certificate of medical necessity |
Find |
^Patient |
Pt |
Doc |
|
|
ACTIVE |
Certificate of Medical Necessity |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ATTACH |
|
103595-5 |
|
|
|
|
Both |
|
|
|
0 |
Cert Med Neces |
|
|
|
N |
|
ATTACH; CertMedNec; Document; Finding; Findings; Point in time; Random |
2.77 |
2.77 |
Y |
|
|
|
|
|
|
|
|
|
|
0 |
103596-3 |
Durable medical equipment proof of delivery receipt |
Find |
^Patient |
Pt |
Doc |
|
|
ACTIVE |
Durable medical equipment proof of delivery receipt |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ATTACH |
|
103596-3 |
|
|
|
|
Observation |
|
|
|
0 |
DME proof of delivery |
|
|
|
N |
|
ATTACH; DME proof of delivery receipt; Document; Finding; Findings; Point in time; Random |
2.77 |
2.77 |
Y |
|
|
|
|
|
|
|
|
|
|
0 |
103597-1 |
Pain management form or template |
Find |
^Patient |
Pt |
Doc |
|
|
ACTIVE |
Pain management form or template |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ATTACH |
|
103597-1 |
|
|
|
|
Observation |
|
|
|
0 |
Pain magt form/template |
|
|
|
N |
|
ATTACH; Document; Finding; Findings; Point in time; Random |
2.77 |
2.77 |
Y |
|
|
|
|
|
|
|
|
|
|
0 |
103598-9 |
Direct antiglobulin test.polyspecific reagent |
PrThr |
RBC^Fetus |
Pt |
Ord |
|
|
ACTIVE |
Direct antiglobulin test.polyspecific reagent [Presence] on Red Blood Cells from Fetus |
|
ADD |
DefinitionDescription |
|
|
|
|
|
Not applicable |
|
|
|
BLDBK |
|
103598-9 |
|
|
|
|
Observation |
|
|
|
0 |
DAT Poly-Sp Reag RBC Fetus Ql |
|
|
|
N |
|
Antiglob; BLOOD BANK; DAGT; DAT; DAT Poly-Sp Reag; DCT; Dir; Direct antiglobulin test.non specific reagent; Direct Coomb; Direct coombs test; Erythrocytes; Fetal; Ordinal; Point in time; poly specific; PR; QL; Qual; Qualitative; Random; Red blood cells; Red blood corpusles; Screen |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103599-7 |
Reason for discharge |
Find |
^Patient |
Pt |
Nom |
|
|
ACTIVE |
Reason for discharge from the intensive care unit |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ADMIN.PATIENT |
|
103599-7 |
|
|
|
|
Both |
|
|
|
0 |
Reason for D/C from ICU |
|
|
|
N |
|
ADMIN; ADMIN.PATIENT; Disch; Finding; Findings; Nominal; Point in time; Random |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
1036-3 |
G Ab |
PrThr |
Ser/Plas^BPU |
Pt |
Ord |
|
|
ACTIVE |
G Ab [Presence] in Serum or Plasma from Blood product unit |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
1036-3 |
|
|
|
|
Observation |
|
|
|
0 |
G Ab SerPl BPU Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; BLOOD BANK; Blood product unit; Blood Product Unit (Pack); Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPl^bpu; SerPlas; Serum; Serum or plasma; SR |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
10360-6 |
DNA single strand Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
DNA single strand IgG Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
arb U/mL |
|
|
|
|
|
|
SERO |
|
10360-6 |
|
|
|
|
Both |
|
|
|
0 |
ssDNA IgG Ser-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Deoxyribonucleic acid; DNass; Immune globulin G; Immunoglobulin G; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Serum; SR; SS; ssDNA; Stranded; Strnd; UniversalLabOrders |
2.73 |
1.0i |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
103600-3 |
Baclofen |
MCnc |
Urine |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Baclofen [Mass/volume] in Urine by LC/MS/MS |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
103600-3 |
|
LC/MS/MS |
|
|
Both |
|
|
|
0 |
Baclofen Ur LC/MS/MS-mCnc |
|
|
|
N |
|
Baclosan; Beklo; DRUG/TOXICOLOGY; Drugs; Gablofen; Kemstro; Level; Liofen; Lioresal; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.77 |
2.77 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
103601-1 |
Staphylococcus aureus MLVA type |
Type |
Isolate/Specimen |
Pt |
Nom |
Molgen |
|
ACTIVE |
Staphylococcus aureus MLVA type in Isolate or Specimen by Molecular genetics method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
103601-1 |
|
Molgen |
|
|
Both |
|
|
|
0 |
S. aureus MLVA type Islt/Spm |
|
|
|
N |
|
Islt; Islt/Spm; Isol; Microbiology; Molecular genetics; Multiple locus variable number tandem repeat; Nominal; o71; PCR; Point in time; Random; S aureus; S. aureus MLVA type; Spec; Staph; Typ; Variable number of tandem repeats; VNTR |
2.77 |
2.77 |
|
|
|
|
|
|
|
|
|
|
|
0 |
103602-9 |
6-Hydroxychlorzoxazone |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
6-Hydroxychlorzoxazone [Mass/volume] in Urine |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
103602-9 |
|
|
|
|
Both |
|
|
|
0 |
6-Hydroxychlorzoxazone Ur-mCnc |
|
|
|
N |
|
2(3H)-Benzoxazolone, 5-chloro-6-hydroxy-; 2-BENZOXAZOLINONE, 5-CHLORO-6-HYDROXY-; 5-Chloro-6-hydroxy-2-benzoxazolinone; 5-chloro-6-hydroxy-3H-1,3-benzoxazol-2-one; 5-Chloro-6-hydroxybenzo[d]oxazol-2(3H)-one; 6-hydroxy Chlorzoxazone; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.77 |
2.77 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
103603-7 |
Tick-borne Ab panel |
- |
Ser |
Pt |
- |
|
|
ACTIVE |
Tick-borne Ab panel - Serum |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
103603-7 |
|
|
|
|
Order |
|
|
|
0 |
STICK Ser |
|
|
|
N |
|
Microbiology; Pan; PANEL.MICROBIOLOGY; Panl; Pnl; Point in time; Random; Serum; SR; STICK |
2.78 |
2.77 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |